Candel Therapeutics (CADL) Retained Earnings (2020 - 2025)
Candel Therapeutics (CADL) posted Retained Earnings of -$230.4 million for Q4 2025, down 14.69% sequentially from -$200.9 million in Q3 2025, and down 19.87% YoY from -$287.5 million in Q4 2024.
Candel Therapeutics (CADL) Retained Earnings (2020 - 2025) Analysis & Trends
Candel Therapeutics has reported Retained Earnings for 6 years, with the latest figure at -$230.4 million in Q4 2025.
- Quarterly Retained Earnings fell 19.87% year-over-year to -$230.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$230.4 million (down 19.87% YoY) and the FY2025 annual result came in at -$230.4 million, down 19.87% from the prior year.
- Retained Earnings retreated to -$230.4 million in Q4 2025 per CADL's latest filing, from -$200.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$65.7 million in Q2 2021 and troughed at -$230.4 million in Q4 2025.
- A 5-year average of -$135.0 million and a median of -$125.9 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2021 and 2025: Retained Earnings sank 81.78% in 2021, then dropped 12.78% in 2025.
- Over 5 years, Retained Earnings stood at -$80.3 million in 2021, then fell by 23.41% to -$99.1 million in 2022, then slumped by 38.29% to -$137.0 million in 2023, then sank by 40.27% to -$192.2 million in 2024, then decreased by 19.87% to -$230.4 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$230.4 million, -$200.9 million, and -$189.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | -230.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -230.40 Mn |
| Sep 30, 2025 | -200.89 Mn |
| Jun 30, 2025 | -189.62 Mn |
| Mar 31, 2025 | -184.83 Mn |
| Dec 31, 2024 | -192.21 Mn |
| Sep 30, 2024 | -178.13 Mn |
| Jun 30, 2024 | -167.49 Mn |
| Mar 31, 2024 | -145.25 Mn |
| Dec 31, 2023 | -137.03 Mn |
| Sep 30, 2023 | -125.90 Mn |
| Jun 30, 2023 | -117.50 Mn |
| Mar 31, 2023 | -107.90 Mn |
| Dec 31, 2022 | -99.09 Mn |
| Sep 30, 2022 | -94.01 Mn |
| Jun 30, 2022 | -85.30 Mn |
| Mar 31, 2022 | -81.17 Mn |
| Dec 31, 2021 | -80.30 Mn |
| Sep 30, 2021 | -81.89 Mn |
| Jun 30, 2021 | -65.73 Mn |
| Dec 31, 2020 | -44.17 Mn |